Cochrane · systematic review · CD013128
Interventions for chronic pruritus of unknown origin
Andrade, A, Kuah, CY, Martin‐Lopez, JE, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
18
current version
GRADE rated
12
No studies
6
Included studies
NR
No studies 6 · 33.3%Ungraded 0 · 0%Very low 9 · 50%Low 3 · 16.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Serlopitant 5 mg compared to placebo for chronic pruritus of unknown origin
Population: chronic pruritus of unknown origin
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Patient‐reported pruritus intensity Serlopitant 5 mg vs placebo | RR 2.06 [1.27, 3.35] | 1 study · 126 participants | Low Downgraded: imprecision, indirectness |
Adverse events Serlopitant 5 mg vs placebo | RR 1.48 [0.87, 2.5] | 1 study · 127 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Health‐related quality of life Serlopitant 5 mg vs placebo | no estimate extracted | 1 study · 127 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Sleep disturbances: number of participants with insomnia Serlopitant 5 mg vs placebo | RR 0.49 [0.24, 1.01] | 1 study · 128 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Depression Serlopitant 5 mg vs placebo | no estimate extracted | NR | No studies |
Patient satisfaction Serlopitant 5 mg vs placebo | no estimate extracted | NR | No studies |
Serlopitant 1 mg compared to placebo for chronic pruritus of unknown origin
Population: chronic pruritus of unknown origin
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Patient‐reported pruritus intensity Serlopitant 1 mg vs placebo | RR 1.5 [0.89, 2.54] | 1 study · 126 participants | Low Downgraded: imprecision, indirectness |
Adverse events Serlopitant 1 mg vs placebo | RR 1.45 [0.86, 2.47] | 1 study · 128 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Health‐related quality of life Serlopitant 1 mg vs placebo | no estimate extracted | 1 study · 128 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Sleep disturbances: number of participants with insomnia Serlopitant 1 mg vs placebo | RR 0.38 [0.17, 0.84] | 1 study · 128 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Depression Serlopitant 1 mg vs placebo | no estimate extracted | NR | No studies |
Patient satisfaction Serlopitant 1 mg vs placebo | no estimate extracted | NR | No studies |
Serlopitant 0.25 mg compared to placebo for chronic pruritus of unknown origin
Population: chronic pruritus of unknown origin
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Patient‐reported pruritus intensity Serlopitant 0.25 mg vs placebo | RR 1.66 [1, 2.77] | 1 study · 127 participants | Low Downgraded: imprecision, indirectness |
Adverse events Serlopitant 0.25 mg vs placebo | RR 1.29 [0.75, 2.24] | 1 study · 127 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Health‐related quality of life Serlopitant 0.25 mg vs placebo | no estimate extracted | 1 study · 127 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Sleep disturbances: number of participants with insomnia Serlopitant 0.25 mg vs placebo | RR 0.6 [0.31, 1.17] | 1 study · 127 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Depression Serlopitant 0.25 mg vs placebo | no estimate extracted | NR | No studies |
Patient satisfaction Serlopitant 0.25 mg vs placebo | no estimate extracted | NR | No studies |